PT-141 (10 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

PT-141 (bremelanotide) is a cyclic heptapeptide that acts as a non-selective agonist across the melanocortin receptor family, with its researched effects attributed mainly to MC3R and MC4R signalling. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published work, not a recommendation for use in humans or animals.

For a 10 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of roughly 3.33 mg/mL (about 3,333 mcg/mL). On a U-100 insulin syringe each single unit (0.01 mL) then holds approximately 33.3 mcg, so a 15-unit draw delivers close to 500 mcg — a convenient round step for the titration table.

Standard (Gradual) Titration Schedule

The gradual schedule reflects a conservative dose-escalation approach, holding the entry-level amount for several weeks before stepping up to manage tolerability, particularly the nausea and flushing reported at higher exposures.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both rubber stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, to limit foaming.
3. Swirl or roll gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (~3.33 mg/mL) and the reconstitution date.
5. Store upright under refrigeration at 2–8 °C between uses, protected from light, and draw each volume with a fresh sterile syringe.

Advanced (As-Needed) Dosing Reference

Beyond the daily titration model, much of the published clinical work on bremelanotide used an episodic, on-demand pattern rather than a fixed daily ladder. The reference figures below express common single-administration amounts at the same ~3.33 mg/mL fill.

Supplies Needed

• PT-141 vials (10 mg): roughly 1 vial covers ~20 doses at 500 mcg; a 16-week daily reference run as tabled draws on multiple vials depending on the step reached.
• Insulin syringes (U-100, 1 mL): one fresh syringe per draw — about 112 for a 16-week daily schedule.
• Bacteriostatic water (10 mL): one bottle reconstitutes several vials; budget extra for a long run.
• Alcohol swabs: a 100-count box comfortably covers several weeks; stock 2–3 boxes for a 16-week schedule.

Protocol Overview

• Research goal: model central melanocortin (MC3R/MC4R) modulation of sexual motivation and arousal pathways.
• Schedule: daily in the titration model, or episodic on-demand in the clinical model.
• Dose band: 500–1500 mcg daily reference range; ~1.75 mg as a single fixed dose.
• Fill: 10 mg lyophilized, reconstituted to ~3.33 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 500 mcg step and hold it for several weeks before considering escalation.
• Keep a fixed cadence in the daily model for steady-exposure comparison, or respect minimum spacing in the episodic model.
• Escalate only after tolerability is established at the prior step.
• Account for transient blood-pressure elevation when modelling dose ceilings.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about 30 days. Let refrigerated solution warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling technique to keep the stopper intact.
• Keep the reconstituted vial shielded from light to protect the peptide.
• Document each draw — date, volume, remaining material — for reproducibility.

How PT-141 Works

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and a metabolite-derived analogue of the melanocortin agonist family. It binds non-selectively across melanocortin receptors, with the researched arousal-related effects attributed chiefly to central MC3R and MC4R activity rather than the peripheral vascular mechanism of PDE5 inhibitors. In published models, MC4R signalling in reward and arousal regions such as the medial preoptic area and nucleus accumbens is associated with increased dopaminergic tone and sexual motivation. Activity at peripheral MC1R is thought to underlie the skin-darkening observed at higher exposures.

Reported Benefits & Side Effects

Benefits observed in studies

• Improvements in sexual desire scores (FSFI-Desire) versus placebo in premenopausal women studied for hypoactive sexual desire disorder.
• Reductions in associated distress measures (FSDS-DAO) in the same population.
• Signals of arousal-related benefit also reported in earlier male studies.
• Acts through a central pathway distinct from peripheral vasodilator mechanisms.

Side effects reported

• Nausea is the most common effect (reported in roughly 40% of subjects), often early in exposure.
• Flushing, headache and injection-site reactions are also frequent.
• Transient increases in blood pressure with a corresponding heart-rate change.
• Hyperpigmentation (skin darkening) with repeated or higher dosing, linked to MC1R activity.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let them dry.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily, then withdraw and apply light pressure.
• Rotate sites systematically (abdomen, thighs) and dispose of sharps in an approved container after a single use.

References

Related Protocols